|
|
HPV E6/E7 mRNA与液基薄层细胞学联合检测在宫颈癌风险预测中的应用及探讨
|
Abstract:
目的：探讨人乳头状瘤病毒(HPV) E6/E7 mRNA与液基薄层细胞学检查(TCT)联合检测在宫颈癌风险预测中的应用价值。方法：选取2023年1月至2024年6月于延安市人民医院行宫颈癌和癌前病变筛查的216例患者作为研究对象，对其资料进行回顾性分析，该部分患者均同时行HPV E6/E7 mRNA与液基薄层细胞学检测联合及组织病理学检查，分析HPV E6/E7 mRNA与液基薄层细胞学单独检测及两者联合检测宫颈癌的灵敏性、特异性、阳性预测值及阴性预测值。结果：216例患者中，HPV E6/E7mRNA与液基薄层细胞学单独检测的敏感性、特异性、阳性预测值、阴性预测值分别为78.41%、42.50%、85.71%、30.91%和71.59%、62.50%、89.36%、33.33%；HPV E6/E7 mRNA与液基薄层细胞学联合检测的敏感性、特异性、阳性预测值、阴性预测值为93.19%、65.00%、92.13%、68.42%，差异均有统计学意义(P < 0.05)。结论：HPV E6/E7 mRNA和液基细胞学联合检测可有效提高宫颈癌及癌前病变的阳性检出率，敏感性和阴性预测值显著提升，与活检金标准的一致性较好，可有效判断HPV的感染状态和严重程度，减少不必要的阴道镜活检，减轻患者心理负担，对宫颈癌的风险预测有很好的应用价值。
Purpose: To explore the application value of HPV E6/E7 mRNA and Thinprep cytologic test (TCT) in predicting the risk of cervical cancer. Methods: 216 patients who underwent HPV E6/E7 mRNA and TCT at Yan’an People’s Hospital from January 2023 to June 2024 were selected as the study subjects. The data were retrospectively analyzed. All patients underwent HPV E6/E7 mRNA combined with TCT and histopathological examination. The sensitivity, specificity, positive predictive value, and negative predictive value of HPV E6/E7 mRNA and TCT detected separately and combinedly for cervical cancer were analyzed. Results: Among 216 patients, the sensitivity, specificity, positive predictive value, and negative predictive value of HPV E6/E7 mRNA and TCT detected separately were 78.41%, 42.50%, 85.71%, 30.91% and 71.59%, 62.50%, 89.36% and 33.33%; The sensitivity, specificity, positive predictive value, and negative predictive value of combined detection of HPV E6/E7 mRNA and TCT were 93.19%,65.00%, 92.13%, and 68.42%, with statistically significant differences (P < 0.05). Conclusion: The combined detection of HPV E6/E7 mRNA and TCT can effectively improve the positive detection rate of cervical cancer and precancerous lesions, significantly increase sensitivity and negative predictive value, and have good consistency with the gold standard for biopsy. It can effectively determine the infection status and severity of HPV, reduce unnecessary colposcopy biopsy, reduce the psychological burden of patients, and have good application value in predicting the risk of cervical cancer.
| [1] | Fokom Domgue, J. and Schmeler, K.M. (2019) Conservative Management of Cervical Cancer: Current Status and Obstetrical Implications. Best Practice & Research Clinical Obstetrics & Gynaecology, 55, 79-92. https://doi.org/10.1016/j.bpobgyn.2018.06.009 |
| [2] | Salavatiha, Z., Farahmand, M., Shoja, Z. and Jalilvand, S. (2021) A Meta‐Analysis of Human Papillomavirus Prevalence and Types among Iranian Women with Normal Cervical Cytology, Premalignant Lesions, and Cervical Cancer. Journal of Medical Virology, 93, 4647-4658. https://doi.org/10.1002/jmv.26928 |
| [3] | Yuan, Y., Cai, X., Shen, F. and Ma, F. (2021) HPV Post-Infection Microenvironment and Cervical Cancer. Cancer Letters, 497, 243-254. https://doi.org/10.1016/j.canlet.2020.10.034 |
| [4] | Chaberek, K., Mrowiec, M., Kaczmarek, M. and Dutsch-Wicherek, M. (2022) The Creation of the Suppressive Cancer Microenvironment in Patients with HPV-Positive Cervical Cancer. Diagnostics, 12, Article No. 1906. https://doi.org/10.3390/diagnostics12081906 |
| [5] | 黄强, 钱永红, 梁宝权, 等. 高危型HPV-E6/E7 mRNA检测在宫颈病变筛查中的临床价值[J]. 检验医学与临床, 2021, 18(5): 636-638. |
| [6] | Giorgi Rossi, P., Carozzi, F. and the New Technology for Cervical Cancer 2 Working Group (2021) p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. JNCI: Journal of the National Cancer Institute, 113, 292-300. |
| [7] | Ren, C., Zhu, Y., Yang, L., Zhang, X., Liu, L., Wang, Z., et al. (2019) Prognostic and Diagnostic Validity of P16/ki-67, HPV E6/E7 mRNA, and HPV DNA in Women with ASCUS: A Follow-Up Study. Virology Journal, 16, Article No. 143. https://doi.org/10.1186/s12985-019-1251-4 |
| [8] | Clifford, G.M., Tully, S. and Franceschi, S. (2017) Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis from HPV Infection to Cervical Cancer. Clinical Infectious Diseases, 64, 1228-1235. https://doi.org/10.1093/cid/cix135 |
| [9] | 康红, 叶延程, 樊平, 等. HPV联合TCT检测在宫颈癌筛查中的应用[J]. 现代肿瘤医学, 2020, 28(2): 283-286. |
| [10] | Zappacosta, R., Caraceni, D., Ciccocioppo, L., Rotondo, T., Capanna, S., Gatta, D.M.P., et al. (2013) Implementing Specificity of HPV-DNA Primary Screening in a Successful Organised Cervical Cancer Prevention Programme. Gynecologic Oncology, 128, 427-432. https://doi.org/10.1016/j.ygyno.2012.11.030 |
| [11] | Zhang, L., Tan, W., Yang, H., Zhang, S. and Dai, Y. (2022) Detection of Host Cell Gene/HPV DNA Methylation Markers: A Promising Triage Approach for Cervical Cancer. Frontiers in Oncology, 12, Article ID: 831949. https://doi.org/10.3389/fonc.2022.831949 |
| [12] | Derbie, A., Mekonnen, D., Woldeamanuel, Y., Van Ostade, X. and Abebe, T. (2020) HPV E6/E7 mRNA Test for the Detection of High Grade Cervical Intraepithelial Neoplasia (CIN2+): A Systematic Review. Infectious Agents and Cancer, 15, Article No. 9. https://doi.org/10.1186/s13027-020-0278-x |
| [13] | Della Fera, A.N., Warburton, A., Coursey, T.L., Khurana, S. and McBride, A.A. (2021) Persistent Human Papillomavirus Infection. Viruses, 13, Article No. 321. https://doi.org/10.3390/v13020321 |
| [14] | Lintao, R.C.V., Cando, L.F.T., Perias, G.A.S., Tantengco, O.A.G., Tabios, I.K.B., Velayo, C.L., et al. (2022) Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines. Frontiers in Medicine, 9, Article ID: 929062. https://doi.org/10.3389/fmed.2022.929062 |
| [15] | 林爽, 王翠峰. HPV E6/E7 mRNA检测在宫颈癌中的研究进展[J]. 现代预防医学, 2018, 45(3): 513-515. |
| [16] | 单继烈, 叶素梅, 王兰英, 等. 液基薄层细胞学检测, 高危型人乳头状瘤病毒-DNA和人乳头状瘤病毒E6/E7 mRNA检测在宫颈癌早期筛查中的临床价值[J]. 中国卫生检验杂志, 2018, 28(6): 667-669, 672. |
| [17] | 秦艳, 朱怡. HPV E6/E7 mRNA联合TCT检测在宫颈癌筛查的临床应用价值[J]. 中国妇幼健康研究, 2020, 31(5): 665-670. |
